MX2012002390A - Heterociclos biciclos y su uso como antagonistas del receptor de quimiocina 2 (ccr2). - Google Patents

Heterociclos biciclos y su uso como antagonistas del receptor de quimiocina 2 (ccr2).

Info

Publication number
MX2012002390A
MX2012002390A MX2012002390A MX2012002390A MX2012002390A MX 2012002390 A MX2012002390 A MX 2012002390A MX 2012002390 A MX2012002390 A MX 2012002390A MX 2012002390 A MX2012002390 A MX 2012002390A MX 2012002390 A MX2012002390 A MX 2012002390A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
bicyclic heterocycles
ccr2 receptor
receptor
ccr2
Prior art date
Application number
MX2012002390A
Other languages
English (en)
Inventor
Johannes Aebi
Alfred Binggeli
Patrizio Mattei
Luke Green
Hans P Maerki
Guido Hartmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012002390A publication Critical patent/MX2012002390A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se relaciona a compuestos bicíclicos nuevos de la fórmula (I), en donde A, L, E, F, G, y, w, n, R1, R2, R3, R4, R5, R6, R7, y, W y n son como se definió en la descripción y en las reivindicaciones, así como sales fisiológicamente aceptables de los mismos. Estos compuestos son antagonistas del receptor CCR2, receptor CCR5 y/o receptor CCR3 y pueden ser utilizados como medicamentos.
MX2012002390A 2009-10-07 2010-10-05 Heterociclos biciclos y su uso como antagonistas del receptor de quimiocina 2 (ccr2). MX2012002390A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172408 2009-10-07
PCT/EP2010/064770 WO2011042399A1 (en) 2009-10-07 2010-10-05 Bicyclic heterocycles and their use as ccr2 receptor antagonists

Publications (1)

Publication Number Publication Date
MX2012002390A true MX2012002390A (es) 2012-04-02

Family

ID=43105073

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002390A MX2012002390A (es) 2009-10-07 2010-10-05 Heterociclos biciclos y su uso como antagonistas del receptor de quimiocina 2 (ccr2).

Country Status (13)

Country Link
US (1) US8471004B2 (es)
EP (1) EP2486042B1 (es)
JP (1) JP5559336B2 (es)
KR (1) KR101451487B1 (es)
CN (1) CN102574858B (es)
AU (1) AU2010305495A1 (es)
BR (1) BR112012008221A2 (es)
CA (1) CA2774215A1 (es)
ES (1) ES2455266T3 (es)
IL (1) IL217965A0 (es)
IN (1) IN2012DN00764A (es)
MX (1) MX2012002390A (es)
WO (1) WO2011042399A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
CN111423454B (zh) * 2020-04-24 2021-06-22 苏州大学 哌嗪类化合物及其在制备趋化因子受体ccr2拮抗剂中的应用
CN113979889A (zh) * 2021-11-09 2022-01-28 西安康福诺生物科技有限公司 一种双官能化聚乙二醇基胺的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3740256A1 (de) 1987-05-14 1988-12-08 Bayer Ag Thiazolo-hydantoine
BR0207952A (pt) * 2001-03-07 2004-07-27 Pfizer Prod Inc Moduladores da atividade de receptores de quimiocina
EP1599206A4 (en) * 2003-02-24 2008-05-21 Merck & Co Inc MODULATORS OF HETEROTRICYLICAMIDE FUSIONED WITH AMINOCYCLOPENTYL OF ACTIVITY OF CHEMOKINE RECEPTORS
ATE411989T1 (de) * 2004-05-26 2008-11-15 Janssen Pharmaceutica Nv Mercaptoimidazole als ccr2-rezeptorantagonisten
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
ATE476424T1 (de) * 2006-04-20 2010-08-15 Hoffmann La Roche Diazepanderivate als modulatoren von chemokinrezeptoren
JP2010533672A (ja) 2007-07-19 2010-10-28 エフ．ホフマン−ラ ロシュ アーゲー 新規ヘテロシクリル化合物およびケモカインアンタゴニストとしてのそれらの使用
RU2010116821A (ru) 2007-10-01 2011-11-10 Ф.Хоффманн-Ля Аг (Ch) N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr

Also Published As

Publication number Publication date
ES2455266T3 (es) 2014-04-15
CN102574858B (zh) 2015-06-24
KR20120051090A (ko) 2012-05-21
CN102574858A (zh) 2012-07-11
IN2012DN00764A (es) 2015-06-26
JP5559336B2 (ja) 2014-07-23
BR112012008221A2 (pt) 2016-03-08
US20110082294A1 (en) 2011-04-07
EP2486042B1 (en) 2014-01-22
AU2010305495A1 (en) 2012-03-15
US8471004B2 (en) 2013-06-25
IL217965A0 (en) 2012-03-29
CA2774215A1 (en) 2011-04-14
KR101451487B1 (ko) 2014-10-15
EP2486042A1 (en) 2012-08-15
WO2011042399A1 (en) 2011-04-14
JP2013506701A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
WO2009010429A3 (en) Novel heterocyclyl compounds and their use as chemokine antagonists
MX2009014002A (es) Derivados imidazol como antagonistas del receptor ccr-2.
MX2009009690A (es) Derivados de tiazolidina como antagonistas del receptor de orexina.
GEP20146124B (en) Novel ccr2 receptor antagonists and usage thereof
TW200738655A (en) Novel bicyclic sulfonamide derivatives
ATE524466T1 (de) 3-azabicycloä3.3.0üoktanverbindungen
ATE483707T1 (de) 2-cyclopropylthiazolderivate
IN2012DN03045A (es)
WO2009013211A3 (en) New pyrazol derivatives
MX2010003621A (es) N-heterociclil biaril carboxamidas como antagonistas del receptor ccr.
TW200745032A (en) Novel heterobicyclic derivatives
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
GEP20125590B (en) Benzazepine derivatives and usage thereof as histamine h3 antagonists
MX2010008993A (es) Derivados de 2-aza-biciclo-[2.2.1]heptano.
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
MX2010001575A (es) Derivados de 1,2-diamido-etileno como antagonistas de orexina.
RS20090208A (en) Pyrazoline compounds as mineralocorticoid receptor antagonists
PH12014501540A1 (en) 4-(benzoimidazol-2-yl) - thiazole compounds and related aza derivatives
MX2010002760A (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3.
MX2012003469A (es) Derivados de imidazopiridina o imidazopirimidina como inhibidores fosfodiesterasa 10a.
MY137609A (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2009008323A (es) Derivados heterociclicos como receptores muscarinicos m3.
ATE475645T1 (de) Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.

Legal Events

Date Code Title Description
FG Grant or registration